Form 4: Coherus BioSciences Director Acquires Stock Options

Charles W. Newton, a director at Coherus BioSciences, acquired stock options for 112,000 shares on June 3, 2024.

Summary

• Charles W. Newton, a director of Coherus BioSciences, Inc. (CHRS), filed a Form 4 on June 5, 2024.
• The filing reports a transaction that occurred on June 3, 2024, where Newton acquired stock options for 112,000 shares of Coherus BioSciences common stock.
• The exercise price of the stock options is $1.76.
• The options vest 100% on June 3, 2025, one year after the grant date, contingent upon Newton's continued service with the company.
• The options expire on June 3, 2034.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing stock option grants. It's neutral in tone, but the grant itself can be seen as a mild positive, indicating confidence from the company in the director's continued service and the company's future prospects.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the reporting person's continued service with the issuer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.

Key Dates